University of Pittsburgh researchers have developed a novel approach for isolating and expanding tumor-infiltrating γδ T cells (TILs) from solid tumors, presenting a significant advancement in immunotherapy. This new method overcomes the limitations of conventional αβ T cell receptor (TCR)-based therapies, which rely on MHC-restricted antigen recognition and are subject to immune escape. The expansion of γδ T cells, which can recognize tumor-specific non-peptide antigens independently of MHC, has shown potential to enhance antitumor activity and provide better outcomes for patients with various solid tumors.